<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The therapy for vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> has known several changes and updates since the use of niacin in the first years of the 20th century </plain></SENT>
<SENT sid="1" pm="."><plain>These modifications were due to the parallel evolution of the concept of vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Initially, treatments in this area were proposed because they were considered vasoactive and able to increase the blood flow of the brain </plain></SENT>
<SENT sid="3" pm="."><plain>After these, other drugs were introduced because they were also able to ameliorate the oxygen usage by the suffering neurons </plain></SENT>
<SENT sid="4" pm="."><plain>The more recent therapeutic proposals were made for drugs active on the metabolic activities of the brain, or with hemorrheological or <z:chebi fb="11" ids="22586">antioxidant</z:chebi> properties </plain></SENT>
<SENT sid="5" pm="."><plain>As a consequence, a large array of different pharmacological properties were considered in proposing the several different kinds of drugs as useful in vascular <z:hpo ids='HP_0000726'>dementia</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>The most recent attempt in this field consists of evaluating the usefulness of traditional antidementia drugs (those with anticholinesterase action) in patients with a prevalence of cerebrovascular disorders </plain></SENT>
</text></document>